Table II.
Top 10 dermatologic medications in the United States Food and Drug Administration Adverse Event Reporting Database (FAERS) associated with taste disturbances, with the corresponding clinical trial data and the number of cases reports or case series in PubMed∗
| Medication | Cases in FAERS (% of all ageusia/dysgeusia/taste disturbance cases | Rank of all medications associated with ageusia/dysgeusia/taste disturbance | Clinical trial data | Case reports/cases series in PubMed, No. |
|---|---|---|---|---|
| Vismodegib (oral) | 1054 (1.69) | 11 of 2591 | 67% ageusia/dysgeusia reported in phase III clinical trials, ageusia/dysgeusia were reported in phase IV trials | 2 |
| Etanercept (injection) | 937 (1.50) | 14 of 2591 | No ageusia/dysgeusia reported in phase III clinical trials, no ageusia/dysgeusia reported in phase IV trials | 1 |
| Terbinafine hydrochloride (oral) | 920 (1.47) | 15 of 2591 | 2.8% ageusia/dysgeusia reported in phase III clinical trials, ageusia/dysgeusia were reported in phase IV trials | 9 |
| Apremilast (oral) | 223 (0.36) | 71 of 2591 | No ageusia/dysgeusia reported in phase III clinical trials, no ageusia/dysgeusia reported in phase IV trials | 1 |
| Methotrexate (oral) | 176 (0.28) | 105 of 2591 | No ageusia/dysgeusia reported in phase III clinical trials, no ageusia/dysgeusia reported in phase IV trials | 1 |
| Secukinumab (injection) | 151 (0.24) | 296 of 2591 | No ageusia/dysgeusia reported in phase III clinical trials, no ageusia/dysgeusia reported in phase IV trials | 0 |
| Spironolactone (oral) | 68 (0.11) | 376 of 2591 | No ageusia/dysgeusia reported in phase III clinical trials, no ageusia/dysgeusia reported in phase IV trials | 0 |
| Isotretinoin (oral) | 57 (0.09) | 430 of 2591 | No ageusia/dysgeusia reported in phase III clinical trials, no ageusia/dysgeusia reported in phase IV trials | 2 |
| Tacrolimus (23 topical, 20 oral) | 43 (0.07) | 689 of 2591 | No ageusia/dysgeusia reported in phase III clinical trials, no ageusia/dysgeusia reported in phase IV trials | 0 |
| Mycophenolate sodium (oral) | 42 (0.07) | 691 of 2591 | No ageusia/dysgeusia reported in phase III clinical trials, no ageusia/dysgeusia reported in phase IV trials | 0 |
∗
There were 62,524 cases of taste disturbances reported to FAERS from January 1, 1969, to December 31, 2019, using the key words ageusia, dysgeusia, and taste disturbance.